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Nasal commensal Staphylococcus
epidermidis enhances interferon-λ-
dependent immunity against influenza
virus
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Abstract
Background: Staphylococcus epidermidis is one of the most abundant colonizers of healthy human mucosa including
that in the respiratory tract. As the respiratory microbiome has been linked to host immune responses, this study
sought to determine the role of nasal mucosa-associated S. epidermidis in innate immune responses against the
influenza A virus (IAV). S. epidermidis strains were isolated from nasal mucus samples of healthy individuals. The effects
of these mucosa-derived commensal strains on interferon (IFN)-dependent innate immunity and IAV infection
dynamics were tested in vitro using normal human nasal epithelial (NHNE) cells and human turbinate mucosa. The
effects of S. epidermidis on antiviral immunity were also tested in vivo using an acute IAV infection mouse model.
Results: Exposure of NHNE cells to nasal mucosa-derived S. epidermidis increased IFN-λ mRNA and secreted protein
levels in the absence of viral stimulation. In the context of IAV infection, NHNE exposure to S. epidermidis prevented an
increase in the viral burden, as revealed by IAV PA mRNA abundance, IAV nucleoprotein levels, and viral titers. S.
epidermidis also enhanced transcription of IFN-stimulated genes independently of Toll-like receptor 2 and further
induced IFN-λ production in IAV-infected cells by promoting phosphorylation of interferon regulatory factor 7. In a
murine infection model, S. epidermidis prevented the spread of IAV to the lungs by stimulating IFN-λ innate immunity
and suppressing IAV replication in the nasal mucosa.
Conclusion: The human nasal commensal S. epidermidis mediates front-line antiviral protection against IAV infection
through modulation of IFN-λ-dependent innate immune mechanisms in the nasal mucosa, thereby demonstrating the
role of host-bacterial commensalism in shaping human antiviral responses.
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Background
The innate immune system of the respiratory epithelium
serves as the first line of defense against respiratory vi-
ruses, including the influenza A virus (IAV), by produ-
cing interferon (IFN), a key molecule in the antiviral
response [1]. IFNs including IFN-α, -β, -γ, and -λ enable
substantial heterogeneity in host responses to respiratory
viral infections, with specific IFNs interacting with dif-
ferent viruses to influence antiviral innate immune re-
sponses in the respiratory epithelium [1, 2]. Emerging
evidence has indicated that among the IFN family of cy-
tokines IFN-λ is a critical immune modulator against
viral infection in the epithelial mucosa and the need for
rapid immune responses to the respiratory virus is ac-
quired by the activation of IFN-λ [3–7]. IFN-λ is be-
lieved to be primarily responsible for protection against
viral invaders in the respiratory tract and to play an im-
portant role in local antiviral innate immunity [3, 5].
However, understanding of the modulators involved in
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IFN-λ production, especially within the context of in
vivo respiratory viral infections, remains limited.
Human mucosal surfaces are in direct contact with the
external environment and are, therefore, susceptible to
invasion and colonization by various pathogens [8].
Studies on the clear reaction of the mucosal microbiome
with the host increasingly take into consideration the
contribution of mucosal immune responses and specific
microbiome-mediated protection against infection from
external pathogens to integrate environmental signals
[9]. Respiratory mucosa, including that of nasal passages,
is constantly exposed to inhaled pathogens, which dir-
ectly impact the mucosal immune mechanisms [9, 10].
Inhaled pathogens encounter the host immune system
for the first time in respiratory mucosa; especially, the
nasal passage and microbial characteristics of the nasal
mucus directly impact the mechanisms of initial
immune responses [11–14]. Thus, insights into the
microbiota of the human nasal mucosa can provide
fundamental information regarding susceptibility to
respiratory viral infections and factors contributing to
related immune mechanisms, such as induction of
IFNs [15, 16]. However, our knowledge of microbial
composition in healthy nasal mucus is limited and
the responses to inhaled pathogens or reasons for
their colonization have not been comprehensively
examined.
Based on increasing evidence of microbiome-regulated
host immune homeostasis [11–13, 15], we assessed the
microbial composition in healthy nasal mucus and sub-
sequently investigated whether nasal commensal con-
tributes to antiviral defense mechanisms in human nasal
mucosa as a signaling modulator of antiviral immunity
against IAV infection. The present study identified
Staphylococcus epidermidis as its most abundant con-
stituent and showed that S. epidermidis which were iso-
lated from healthy human nasal mucus accelerated the
clearance of IAV from nasal epithelium through IFN-λ-
related immune responses. Furthermore, human nasal
commensal S. epidermidis prevents IAV lung infection
in mice by enhancing IFN-λ-related innate immune
responses in the nasal mucosa. Overall, we present evi-
dence of a key mechanistic link between the susceptibil-
ity to viral infections and nasal microbiome-mediated
innate immunity.
Methods
Additional methodological details are available in
Additional file 1.
Participant recruitment
Information on the 37 healthy subjects enrolled in
this study and the exclusion criteria are described in
Additional file 1. Participation was voluntary, with
written informed consent obtained from all subjects.
The Institutional Review Board of the Seoul National
University College of Medicine approved the protocol
for this study (IRB #C2012248 [943]).
Sample collection
Mucus and/or nasal mucosa from the middle turbinates
of the human subjects were collected and assessed for
quality as described in Additional file 2: Movie S1).
Nasal mucus microbiome characterization
For bacterial colony isolation, the mucus was placed in
lysogeny broth (LB) plates. After 2 days incubation,
bacterial colonies were obtained from the LB plates
(Additional file 1: Figure S2) and the species of each col-
ony were identified using GS-FLX 454 pyrosequencing
by 16S rRNA gene amplification. S. epidermidis strains
(N1-N4) from four individuals were used in the study
(Additional file 1: Figure S2).
Viruses and reagents
Influenza A virus strain A/Wilson-Smith/1933 H1N1
(IAV A/WS/33; ATCC, Manassas, VA, USA) was used in
this study. Viruses were cultured and titrated using
Madin-Darby canine kidney (MDCK) cells according to
standard procedures [14].
Cell culture and infection
Normal human nasal epithelial (NHNE) cells from five
subjects were cultured using an air-liquid interface
method [17]. Cells were used 14 days following the cre-
ation of the air-liquid interface. S. epidermidis and/or
IAV infections are described in Additional file 1.
Real-time PCR
Levels of transcripts encoding IFN-α, IFN-β, IFN-λ1,
IFN-λ2/3, and IFN-γ, or IAV PA were determined using
real-time PCR as described in Additional file 1.
Quantification of secreted IFN-λ
Secreted human IFN-λ and mouse IFN-λ2/3 were quanti-
fied using Human IL-29/IL-28B (IFN-lambda 1/3) and
Mouse IL-28A/B (IFN-lambda 2/3) DuoSet ELISA kits
(R&D Systems, Minneapolis, MN USA), respectively.
The working range of the assays was 62.5-4000 pg/ml.
Viral titer determination
Viral titers were determined using a plaque assay as de-
scribed in Additional file 1.
Western blot analysis
IAV nucleoprotein (NP) levels and phosphorylation of
IFN regulatory factor (IRF)3 and IRF7 were assessed
using western blotting as described in Additional file 1.
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Murine infection model
Experiments with 7-week-old male C57BL/6J (B6) mice
(Orientalbio, Seoul, Korea) were carried out according
to guidelines approved by the Institutional Review Board
of the Seoul National University College of Medicine
(IACUC #2016-0093). Microbiome depletion, S. epider-
midis and IAV infection, nasal lavage (NAL) and bron-
choalveolar lavage (BAL) sample collection, and lung
tissue harvesting are described in Additional file 1.
Histological analysis
Fixing, hematoxylin/eosin staining, and histological ana-
lysis of the mouse lung tissues were carried out as de-
scribed [18]. Peribronchiolar inflammation was scored
using an 8-point scale. Lung sections from at least five
mice, with at least six areas from each section, were ex-
amined. The five best sections were used for evaluation.
Statistical analyses
The in vitro studies were performed at least in four in-
dependent cultures of NHNE cells from each donor. Dif-
ferences between treatment groups were evaluated by
analysis of variance (ANOVA) with a post hoc test.
Between-group differences in studies in vivo, performed
using five mice, were determined using Mann-Whitney
U tests. Statistical analyses were performed using Graph-
Pad Prism (v.5; GraphPad Software, La Jolla, CA, USA).
A p value < 0.05 was considered significant.
Results
Characterization of bacterial communities in healthy nasal
mucus
The local microbiome of the middle turbinate mucus of
healthy human subjects (N = 20) was analyzed by cul-
tured bacterial colony and 16S rRNA gene sequencing.
Based on at least 97% sequence identity, 46 bacterial
species were detected in the middle turbinate mucus. S.
epidermidis, Corynebacterium pseudodiphtherticum, En-
terobacter aerogenes, Citrobacter koseri, Klebsiella pneu-
moniae, Corynebacterium accolens, Staphylococcus
aureus, and Apteryx australis were among the most
commonly identified species. S. epidermidis demon-
strated the highest abundance, accounting for 35.53% of
the mapped sequences (Fig. 1a). The abundance of nasal
commensal S epidermidis was different in each patient,
and the highest distribution reached 54.2%. The lowest
abundance of S. epidermidis was 12.3% in the nasal com-
mensal of healthy nasal mucus (Fig. 1b). To assess the
role of this commensal organism in human nasal mucus,
S. epidermidis strains isolated from four subjects (N1,
N2, N3, and N4) were analyzed.
S. epidermidis pretreatment suppresses IAV replication in
the nasal epithelium
To analyze the effects of S. epidermidis pretreatment on
the susceptibility of the nasal epithelium to IAV infec-
tion, NHNE cells from five healthy subjects were in-
fected with IAV at a multiplicity of infection (MOI) of 1.
Subsequently, IAV levels were assessed in the superna-
tants and cell lysates harvested at different time points
post-infection. Real-time PCR revealed that IAV PA
mRNA levels increased significantly starting at 1 day
post-infection (dpi; mean IAV mRNA: 2.1 × 105, 1 dpi;
2.4 × 105, 2 dpi; 8.1 × 105, 3 dpi; Fig. 1c). Plaque assays
also found increased IAV titers starting at 1 dpi and a
peak titer of 5.8 × 104 plaque-forming units (PFU)/ml
was observed at 3 dpi (Fig. 1d). Western blot analysis
similarly revealed that IAV NP levels significantly in-
creased by 1 dpi and continued to increase through to 3
dpi (Fig. 1e). These findings demonstrated the significant
susceptibility of the nasal epithelium to IAV infection
from 1 dpi.
To examine the effect of S. epidermidis on the antiviral
immune response, NHNE cells were treated with S. epi-
dermidis N1 (MOI = 0.25) at 8 h before inoculation of
IAV (MOI = 1). The increase in IAV PA mRNA level
(4.2 × 104) in IAV-infected NHNE cells at 1 dpi was
significantly attenuated by S. epidermidis (1.3 × 102)
(Fig. 1f ). Viral titers were also significantly lower in the
supernatants of NHNE cells co-infected with IAV and S.
epidermidis than in those of cells infected with IAV
alone (Fig. 1g). Similarly, S. epidermidis exposure also
decreased IAV NP levels in IAV-infected NHNE cells
(Fig. 1h). Interestingly, no reduction in viral load was ob-
served in IAV-infected NHNE cells which were inocu-
lated with boiled S. epidermidis (Fig. 1i). S. epidermidis
strains isolated from the nasal mucus of other healthy
subjects (N2, N3, and N4) also reduced IAV viral titer
and protein levels (Fig. 1j, k). However, viral titers and
NP levels were not reduced in NHNE cells infected with
a non-pathogenic laboratory S. epidermidis ATCC 12228
strain [19] before IAV. These findings suggested that
commensal S. epidermidis native to the human nasal
passages can specifically suppress IAV replication in
nasal epithelium.
S. epidermidis preferentially induces IFN-λ in NHNE cells
To assess the mechanisms of the S. epidermidis-
dependent antiviral immune response in the nasal epi-
thelium, we measured the expression of IFN genes in S.
epidermidis-exposed NHNE cells. S. epidermidis isolated
from healthy individuals (N1, N2, N3, and N4) signifi-
cantly elevated the levels of IFNL1 and IFNL2/3 mRNA
in NHNE cells starting at 8 h after treatment, with max-
imum levels observed 24 h after infection (IFNL1 6.4 ×
103, IFNL2/3 1.1 × 104, Fig. 2a). S. epidermidis similarly
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induced the secretion of IFN-λ (1 dpi, 586.4 pg/ml, Fig. 2b)
but did not increase the expression of genes encoding IFN-
α, IFN-β, and IFN-γ.
When NHNE cells were inoculated with S. epider-
midis prior to IAV, S. epidermidis induced IFN-λ
more significantly in IAV-infected NHNE cells. NHNE
cells treated with nasal commensal S. epidermidis 8 h
before IAV infection demonstrated higher levels of
gene expression (IFNL1 4.2 × 104, IFNL2/3 4.8 × 104)
and secretion of IFN-λ (1412.4 pg/ml) than cells
infected with IAV alone (IFNL1 5.6 × 103, IFNL2/3
2.7 × 103, 511.5 pg/ml) (Fig. 2c, d). However, pretreat-
ment of NHNE cells with the non-pathogenic labora-
tory S. epidermidis ATCC 12228 strain before IAV
infection did not result in a similar induction. Con-
sidering the more significant induction of IFN-λ ob-
served, we subsequently assessed the effect of S.
epidermidis on mRNA levels of the IFN-stimulated
genes (ISGs) encoding CXCL10, IFIT1, Mx1, and
OAS1, which are required for the innate immune re-
sponse against IAV. Transcript levels of all four genes
were significantly elevated in nasal commensal S. epi-
dermidis-treated NHNE cells before IAV infection
(CXCL10 1.9 × 104, IFIT1 1.7 × 104, Mx1 7.4 × 103,
OAS1 7.1 × 103) (Fig. 2e) relative to untreated cells
and those infected with IAV alone. In contrast, no in-
duction was observed in cells pretreated with S. epi-
dermidis ATCC 12228 prior to IAV infection.
As a next step, NHNE cells were transfected with
short hairpin (sh)RNA of IL28R, which is a region of the
IFN-λ receptor, to cause a functional loss of the IFN-λ-
related signaling pathway. Interestingly, the significant
decrease of IAV PA mRNA level (2.1 × 104) and viral
titer (1.1 × 106 pfu/ml) in S epidermidis-treated NHNE
cells before IAV infection was not observed in NHNE
cells with transfection of IL28R shRNA (Fig. 2f, g). These
data suggested that nasal commensal S. epidermidis in-
duces IFN-λ production and secretion and facilitates
IFN-related innate immune responses against IAV.
S. epidermidis promotes IAV clearance independently of
pattern recognition receptors
To further investigate the mechanisms of significant
IFN-λ induction by nasal mucus-derived S. epidermi-
dis, we assessed mRNA levels of genes encoding pat-
tern recognition receptors in NHNE cells infected
with IAV in the absence or presence of S. epidermidis
pretreatment. Transcripts encoding TLR2, TLR3, RIG-
I, and MDA5 were not more elevated in NHNE cells
treated with S. epidermidis and IAV relative to those
in cells infected with IAV alone (Additional file 1:
Figure S1). The transcription levels of TLR2 mRNA
was higher in S. epidermidis-inoculated NHNE cells
than TLR3, RIG-I, and MDA5 at 1 dpi (Fig. 3a). Thus,
we next assessed the impact of TLR2 on S. epidermi-
dis-dependent modulation of IAV infection by trans-
fecting NHNE cells with shRNA to suppress the
expression of TLR2 mRNA. Suppression of TLR2 ex-
pression prior to IAV infection did not alter S. epider-
midis-dependent effects on IAV PFU levels. Viral
titers were reduced in NHNE cells treated with S. epi-
dermidis before IAV infection (1.3 × 104 pfu/ml) rela-
tive to those in cells infected with IAV alone in a
manner independent of TLR2 shRNA (4.3 × 105 pfu/
ml) (Fig. 3b).
To assess the S. epidermidis-related modulation of
IFN-λ expression at the transcription level, we investi-
gated the phosphorylation states of IFN regulatory factor
(IRF) 3 and IRF7, which are required for transcription of
IFN-λ in respiratory epithelium. Although total levels of
IRF3 and IRF7 remained unchanged, those of the re-
spective phosphorylated proteins were elevated in IAV-
infected NHNE cells at 1 dpi relative to non-treated
cells. Interestingly, levels of phosphorylated IRF7 were
further increased in NHNE cells treated with S. epider-
midis before IAV infection relative to those in cells
infected with IAV alone (Fig. 3c). Together, these find-
ings indicated that nasal commensal S. epidermidis can
promote phosphorylation of IRF7 to induce IFN-λ
(See figure on previous page.)
Fig. 1 S. epidermidis exerts an antiviral effect against influenza A virus (IAV) infection in normal human nasal epithelial (NHNE) cells. a Bacterial species
cultured from mucus samples obtained from the middle turbinates of healthy human subjects (n = 20) were identified via 16S rRNA gene sequencing.
The distribution of the identified bacterial species is presented in the graph. b The relative abundance of nasal commensal, such as S. epidermidis, C.
pseudodiphtheriticum, and E. aerogenes, in each subject. Bar graph presents the relative abundance of nasal commensal at the species level. NHNE cells
from five healthy volunteers were inoculated with IAV at a multiplicity of infection (MOI) of 1. c IAV PA mRNA levels, normalized to cellular GAPDH
transcript levels, were monitored by real-time PCR over the course of 3 days. d Viral titer of the infected NHNE cells was monitored using plaque
assays. Results are presented as the mean ± standard deviation (SD) from five independent experiments. *p < 0.05 compared with mock-infected cells.
e Levels of IAV nucleoprotein (NP) were monitored in NHNE cells following IAV infection using western blot analysis. Representative results are shown.
PI post-infection. NHNE cells were inoculated with S. epidermidis N1 (MOI = 0.25) 8 h before IAV infection (MOI = 1). Subsequently, IAV PA mRNA levels
(f), viral titers (g), and IAV NP protein levels (h) were assessed at 1 day post-infection (dpi) using real-time PCR, plaque assays, and western blotting,
respectively. The mean viral titer was also measured in NHNE cells which were inoculated with boiled S. epidermidis and non-boiled S. epidermidis 8 h
before IAV infection (i). Both mean viral titers (j) and IAV NP level (k) were determined at 1 dpi for NHNE cells infected with nasal mucus-derived S.
epidermidis (N1, N2, N3, N4) and or non-pathogenic laboratory S. epidermidis ATCC 12228 prior to IAV infection. Real-time PCR and plaque assay results
are presented as mean ± SD from five independent experiments. *p < 0.05 compared with the values for cells infected with IAV alone
Kim et al. Microbiome            (2019) 7:80 Page 5 of 12
expression and can suppress IAV replication independ-
ently of TLR2.
S. epidermidis abundance and IFN-λ expression are
positively correlated in human nasal mucosa
Considering the in vitro effect of nasal commensal S.
epidermidis strains on IFN expression and IAV infec-
tion, we next investigated the relationship between S.
epidermidis abundance and IFN-λ mRNA levels.
Nasal mucus and middle turbinate mucosa of 17
healthy subjects were collected and assessed for the
number of S. epidermidis colony-forming units (CFU)
and IFN-λ1 and IFN-λ2/3 mRNA levels were mea-
sured using turbinate mucosa. Nasal commensal S.
epidermidis CFUs positively correlated with mRNA
levels of IFN-λ1 (r = 0.566, p = 0.018) and IFN-λ2/3
(r = 0.446, p = 0.049) in the nasal mucosa of the
same subjects (Fig. 3d, e). These data indicated that
the levels of S. epidermidis in the nasal mucus pro-
portionally affect the transient expression of IFN-λ in
nasal mucosa.
S. epidermidis pretreatment prevents IAV lung infection in
vivo through suppression of IAV replication in the nasal
mucosa.
Considering our observations, we next assessed the S.
epidermidis anti-IAV protective properties in vivo using
a murine model of infection. The nasal cavities of B6
Fig. 2 Influenza A virus (IAV) and S. epidermidis induce the expression of interferon (IFN) and IFN-stimulated genes (ISGs). Normal human nasal
epithelial (NHNE) cells were inoculated with nasal mucus-derived S. epidermidis (N1, N2, N3, N4) at a multiplicity of infection (MOI) of 0.25. a
Levels of mRNAs encoding IFNs were monitored by real-time PCR. b NHNE cell supernatants were assayed by ELISA for levels of secreted IFN-λ
following S. epidermidis infection. IFN-λ mRNA abundance (c), IFN-λ protein levels (d), and ISG mRNA levels (e) were also assessed in NHNE cells
infected with S. epidermidis and/or IAV. IAV PA mRNA levels (f) and viral titers (g) were also measured in NHNE cells which were transfected with
control shRNA or IL28R shRNA. Results are presented as the mean ± SD from four independent S epidermidis experiments. *p < 0.05 compared
with control NHNE cells. **p < 0.01 compared with NHNE cells infected with IAV alone
Kim et al. Microbiome            (2019) 7:80 Page 6 of 12
mice (N = 4) were inoculated with human nasal mucus-
derived S. epidermidis at 2 days (day 5) following nasal
microbiota-depletion (days 1, 2, and 3) using 30 μl of an
antibiotic cocktail (vancomycin, neomycin, ampicillin,
and metronidazole). Then, S. epidermidis-inoculated B6
mice were infected with IAV (213 pfu/30 μl) at 2 days
after S. epidermidis inoculation (day 7) (Fig. 4a).
As gross determinants of virus-induced morbidity, the
body weights and survival rates of the infected B6 mice
were monitored for 7 days. IAV-infected mice exhibited
a significant decrease in mean body weight with an 80%
survival rate until 7 dpi. Interestingly, B6 mice that were
administered human nasal mucus-derived S. epidermidis
before IAV infection did not exhibit a significant weight
loss until 7 dpi and the mean body weight of these mice
exceeded 20 g until 7 dpi resulting in 100% survival of
mice after IAV infection (Fig. 4b).
Compared to mice infected with IAV alone (2.8 × 105),
those infected with IAV following S. epidermidis inocula-
tion showed lower IAV PA mRNA levels (4.2 × 104) in
the lung tissue (Fig. 4c) and the S. epidermidis/IAV
exposure also resulted in attenuated pathologic findings
in the lung, with significantly lower histologic scores
(Fig. 4d). However, significant lung pathologic findings
were obtained from B6 mice that were administered the
non-pathogenic laboratory S. epidermidis ATCC 12228
strain before IAV infection compared to the mice that
were inoculated with human nasal mucus-derived S. epi-
dermidis (Fig. 4e).
We next assessed the distribution of bacteria in S. epi-
dermidis-inoculated mice by comparing the CFUs in the
NAL and BAL samples. Whereas substantial numbers of
S. epidermidis CFUs were observed in the NAL samples,
the levels of S. epidermidis cells in the BAL samples
were under the detection limit (Fig. 4f ). We also asked
whether these differences in S. epidermidis distribution
translate into specific patterns of IFN-λ expression in
the mice. IAV infection alone resulted in elevated
IFNL2/3 gene expression in the nasal mucosa and lung
tissue, as well as in increased secreted IFN-λ levels in
NAL and BAL samples. Gene expression induction and
IFN secretion were further enhanced in the nasal mu-
cosa and the NAL fluid, respectively, of IAV-infected
mice pre-inoculated with S. epidermidis. However, IFN-
λ2/3 mRNA and IFN-λ protein levels were not detectable
in the lung tissue and BAL fluid of these pre-inoculated
Fig. 3 S. epidermidis induces interferon (IFN)-λ independently of pattern recognition receptors. a Abundance of transcripts encoding TLR2, TLR3, RIG-I,
and MDA5 in normal human nasal epithelial (NHNE) cells infected with S. epidermidis 8 h before influenza A virus (IAV) infection was measured using
real-time PCR at 1 day post-infection (dpi). b NHNE cells were transfected with control shRNA and TLR2 shRNA, and plaque assays were performed to
measure viral titers of IAV-infected NHNE cells in the presence or absence of S. epidermidis. Results are presented as the mean ± SD from four
independent experiments. *p < 0.05 compared to control NHNE cells. c IAV- and S. epidermidis-induced phosphorylation of IFN regulatory factor (IRF) 3
and IRF7 was assessed using western blot analysis. The mRNA levels of IFN-λ1 (d) and IFN-λ2/3 (e) in the nasal mucosa from middle turbinate of healthy
volunteers (n = 17), as measured by real-time PCR, were correlated with the colony-forming units (CFUs) of S. epidermidis isolated from the mucus of
the middle turbinate collected from the same subjects. The correlation was determined by Spearman’s correlation analysis
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animals accompanied with completely lower viral repli-
cation in vivo lung (Fig. 4g, h). Together, these findings
demonstrated that the human nasal commensal S. epi-
dermidis can boost the IFN-λ-dependent innate immune
response in mouse nasal mucosa, thereby suppressing
IAV replication at the level of the nose and preventing
acute IAV lung infection.
Discussion
Our study revealed that S. epidermidis is the most abun-
dant microbiome that colonizes healthy human nasal
mucus and the distribution of S. epidermidis might be
significantly associated with IFN-λ-dependent innate im-
mune responses in the nasal mucosa. Our findings also
imply that the intranasal administration of S. epidermidis
is a potential strategy for the prevention of respiratory
viral infections by controlling viral replication at the
level of the nasal mucosa. This study presents novel evi-
dence of the role played by the healthy human nasal
microbiome in the defense against IAV replication in the
nasal mucosa.
Respiratory mucosa is the first target organ for envir-
onmental pathogens, including respiratory viruses. Re-
cent work has highlighted the critical role of respiratory
mucosa as a barrier for restricting the invasion of the
host by multiple pathogens [10, 20–22]. The compos-
itional and predicted functional differences in the re-
spiratory microbiome resulting from environmental
stimuli have been gaining increasing interest and the im-
portance of the respiratory microbiome, especially with
respect to immune protection, has been greatly recog-
nized [23–28]. Therefore, understanding the compos-
ition and potential adverse changes in the respiratory
mucosal microbiome is essential for developing new ap-
proaches for the prevention and treatment of respiratory
infections. The nasal mucosa is also a key player in im-
munological defense to protect the respiratory tract and
is responsible for filtration of inhaled pathogens from
direct exposure to pressurized airflow [21, 22]. There is
also growing evidence that a microbiome community re-
sides in the nasal mucus, which is secreted by epithelial
cells, and covers the whole surface of the mucosa, and
we found that S. epidermidis is the most abundant com-
mensal organism in the human nasal mucus, accounting
for ~ 35% of the identified bacterial species. Human
respiratory viruses first encounter host defense mecha-
nisms in the upper or lower respiratory epithelium [29–
34]. Host protection against viral infections can be con-
ferred by innate resistance, with a specialized innate im-
mune system of nasal epithelium capable of combating
invasion by respiratory viruses [10]. Thus, we focused on
the contribution of S. epidermidis to antiviral innate im-
mune defense mechanisms of the nasal mucosa.
Antiviral innate immunity in the respiratory tract is
mediated by an increase in IFN secretion [35–41]. The
role of type 1 IFNs in antiviral innate immune responses
and the activation of the adaptive immune system have
been well documented [42–44]. Increasing evidence
shows that IFN-λ is also critical for antiviral innate
immunity in the respiratory tract, with disrupted IFN-λ-
related innate immunity increasing susceptibility to
respiratory viral infections [45–48]. Some studies have
reported that IFN-λ is the primary cytokine that medi-
ates the antiviral response against rhinovirus and influ-
enza virus in the lungs [46, 49–51]. We have also
reported that IFN-λ represents the predominant IFN
type induced by IAV and contributes to the first-line
defense against viral infections in human nasal epithelial
cells [10]. We have concentrated on verifying the im-
mune mediators for IFN-λ in the nasal mucosa and
propose that IFN-λ can be regulated by the nasal micro-
biome, with S. epidermidis as the most abundant com-
mensal organism. Here, we found that nasal commensal
S. epidermidis showed potent antiviral activity in nasal
epithelium and all ensuing antiviral responses from S.
epidermidis are dependent on the production of IFN-λ
without affecting IFN-α, IFN-β, and IFN-γ expression
because responses are lost in nasal epithelial cells lacking
specific receptors for IFN-λ, as shown in Fig. 2f and g.
This hypothesis is underscored by the positive correl-
ation between IFN-λ mRNA levels of nasal mucosa and
S. epidermidis colony numbers in human nasal mucus.
(See figure on previous page.)
Fig. 4 Human nasal mucus-derived S. epidermidis induces interferon (IFN)-λ production and suppresses infection spread in influenza A virus (IAV)-
infected mice. a Schematic of the mouse model experimental design. The native microbiome of the C57BL/6J mice was depleted with an antibiotic
regimen prior to inoculation. The mice (N = 4) were inoculated with S. epidermidis (3.2 × 106 CFU/30 μl PBS) and/or with IAV (213 PFU) at the indicated
time points. b Mean body weight of S epidermidis-inoculated mice with or without IAV infection was measured. IAV PA mRNA levels in the mouse lung
tissue (c) were assessed at 7 days post-infection (dpi) and hematoxylin and eosin (H&E)-stained micrographs (d) were also generated from lung
sections obtained at 7 dpi. B6 mice were inoculated with human nasal mucus-derived S. epidermidis and non-pathogenic laboratory S. epidermidis
12228 before IAV infection and H&E-stained micrographs (e) were also generated from lung sections obtained at 7 dpi. Micrographs shown are
representative of lung sections from four mice. The micrographs were used to assess inflammation and tissue damage and to calculate a histological
score. f S. epidermidis CFUs in the NAL and BAL fluid samples were determined at 7 dpi. g IFN-λ2/3 mRNA levels in mouse nasal mucosa and lung
tissue at 7 dpi were measured using real-time PCR. h Concentrations of mouse NAL and BAL fluid samples were compared to secreted IFN-λ
concentrations using ELISA. Real-time PCR, plaque assay, and ELISA results are presented as mean ± SD from four independent experiments. *p < 0.05
compared with mice infected with IAV alone
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Thus, a higher abundance of S. epidermidis in the nasal
mucus of healthy individuals results in higher baseline
IFN-λ levels in the absence of a viral infection.
We furthermore demonstrated that the nasal com-
mensal S. epidermidis confers protection against IAV in-
fection. Relative to infection with IAV alone, inoculation
of S. epidermidis before IAV infection reduced the viral
burden of NHNE cells, while concomitantly inducing
IFN-λ and ISG expression. Previous research has shown
that S. epidermidis directly binds influenza virus, with
the extracellular matrix-binding protein Embp identified
as a major contributor to the anti-influenza effect of S.
epidermidis ATCC 12228 [19]. However, in our in vitro
system using full differentiated human nasal epithelium,
the laboratory S. epidermidis ATCC 12228 strain was
not capable of reducing the viral burden of IAV-infected
NHNE cells or of inducing IFN-λ production. We specu-
late that the nasal commensal S. epidermidis possess
specific characteristics, distinct from those of non-
pathogenic laboratory S. epidermidis ATCC 12228 or of
respiratory tract pathogens, that allow it to boost base-
line immune mechanisms through IFN-λ. These findings
suggest that commensal S. epidermidis specifically from
human nasal mucus shows distinctive antiviral immune
responses against IAV through induction of IFN-λ from
at least 8 h after inoculation.
In addition to showing in vitro activity in NHNE cells,
nasal mucus-derived S. epidermidis also suppressed IAV-
caused lung infection in vivo. Inoculation of mice with
human commensal S. epidermidis strains prior to IAV
infection increased the expression of IFN-λ in the mouse
nasal mucosa and prevented IAV-induced lung tissue
damage. We hypothesize that the mice that received the
human commensal bacteria prior to IAV infection had
limited IAV replication in their nasal mucosa, thereby
preventing acute lung infection. We did not observe dir-
ect binding between human commensal S. epidermidis
and IAV in vitro or in vivo.
The current findings indicate that nasal commensal S.
epidermidis could be detected by TLR2 in the nasal epi-
thelium but S. epidermidis induced IFN-λ through direct
signal transduction to transcription factors regardless of
recognition by TLR2. Both IRF3 and IRF7 have been
characterized as transcription factors for IFNs and IFN-λ
induction depends on direct signal transduction through
the phosphorylation of IRF3 and IRF7 [48, 52]. While
IRF3 is generally regarded as the transcription factor re-
quired for the initiation of IFN transcription, IRF3 defi-
ciency has little impact on IFN expression [52]. In
contrast, lack of IRF7 reduced IFN production signifi-
cantly in airway epithelium [52]. Our data explain how
nasal commensal S. epidermidis could promote phos-
phorylation of IRF7 rather than IRF3 and finally induce
IFN-λ-related immune responses in nasal epithelium.
We did not show the definite paradigm for S. epidermi-
dis-enhanced phosphorylation of IRF7 in nasal epithe-
lium. We just speculate that S. epidermidis-secreted
molecules interact with IRF7 and are primarily respon-
sible for the phosphorylation of IRF7 for the more po-
tent induction of IFN-related antiviral immune
responses in airway epithelium.
As shown in Fig. 1i and j, it is of interest that the non-
pathogenic S. epidermidis strain (ATCC #12228) failed
to induce protective effects against IAV infection. This
supports the notion that the S. epidermidis strains recov-
ered from the human nasal cavity might have acquired
novel genetic features during the long-term symbiosis in
the human nasal mucosa. The comparative genomic
analysis will provide insights into the genetic determi-
nants that help us understand mechanisms by which our
innate immunity is activated in response to the symbi-
otic interaction with a commensal microbe.
Conclusion
Our study provides a greater understanding of how the
nasal microbiome enhances IFN-dependent innate im-
mune responses to protect the respiratory tract against
influenza viral infection. We showed that the abundant
human nasal commensal organism S. epidermidis en-
hances resistance against IAV infection in human nasal
epithelium through IRF7-dependent IFN-λ amplification
and prevents IAV lung infection through the suppression
of IAV replication at the level of the nasal mucosa. Thus,
intranasal delivery of the human nasal commensal S. epi-
dermidis represents a potential therapeutic approach for
preventing and treating respiratory viral infections via
induction of IFN-λ-related innate immune responses.
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